- IMU Biosciences has extended its Series A to over $53 million in an oversubscribed round co-led by IQ Capital and Molten Ventures, with support from the British Business Bank and Meltwind alongside existing investors.
- The London-based company has built the world’s largest immune dataset, scaling to more than 25,000 individuals and over 100 million immune data points measurable from a single blood sample.
- Buildings account for roughly 39% of global carbon emissions — and in precision medicine, the immune system may be the equivalent missing variable: present in every major disease, yet still poorly mapped at clinical scale.
Doctors can sequence your entire genome. They still cannot fully read your immune system, the biological layer that determines whether a cancer treatment works, whether a transplanted organ survives, or whether the body attacks itself. IMU Biosciences just raised $53 million to change that.
The London-based biotechnology company has announced an oversubscribed extension to its Series A, bringing total Series A funding to more than $53 million. The round was co-led by IQ Capital and Molten Ventures, with participation from the British Business Bank and Meltwind alongside existing investors. Molten Ventures is IMU’s largest shareholder.
The latest raise follows IMU’s earlier funding rounds, including an $11.5 million investment announced in 2024 to advance its AI-driven precision medicine platform.
From leading UK research institutes to immune system decoding
IMU Biosciences was founded in 2021 by Dr Adam Laing, Dr Tom Hayday, and Mario Cantero, based on ten years of research from King’s College London and The Francis Crick Institute. Laing now serves as President and Chief Scientific Officer; Hayday is Chief Scientific Officer; and Cantero is Chief Operating Officer. In September 2024, Dr John Baker joined as CEO, bringing executive experience from Abcam, where he served during the company’s $5.7 billion acquisition by Danaher.
The founding team saw a fundamental limitation in how immune systems are currently analysed. Existing tools often provide fragmented snapshots rather than a complete picture, making it difficult to understand disease progression, treatment response, or patient-specific immune behaviour. IMU’s CytAtlas platform combines advanced multi-omic profiling with machine learning to create what it calls a high-definition map of the immune system, generating over 100 million immune data points from a simple blood sample.
The company is scaling its dataset to more than 25,000 individuals through access to patient samples and population-wide clinical data.
Investors’ attention
The immune system sits at the centre of some of healthcare’s biggest challenges, predicting cancer immunotherapy response, monitoring transplant rejection, identifying early disease signals. IMU is building a universal standard for immune profiling spanning stem cell transplantation, solid organ transplantation, and MANIFEST, a major UK research consortium investigating patient responses to cancer immunotherapies.
Dr Inga Deakin, Partner at Molten Ventures says, “When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could transform precision medicine. Since then, the team has consistently delivered. The immune system sits at the heart of almost every disease, and IMU’s ability to analyse it at this resolution could redefine how treatments are matched to patients. We’re proud to be IMU’s largest shareholder and excited to support the company’s next phase of growth.”
Dr Alex Wilson, Partner at IQ Capital notes, “We’re thrilled to support IMU as a co-lead investor in this round. With the world’s largest immune dataset and proprietary machine learning analytics, the company is unlocking the value of health data to deliver better insights for clinicians and improved outcomes for patients. We’re excited to be part of IMU’s next stage of growth.”
Dr Carmine Circelli, Senior Investment Director, Life Sciences at British Business Bank, notes, “IMU combines proprietary data scale with deep biological insight. By creating an unprecedented view of the human immune system, the company is building a platform with the potential to transform how disease is understood and treated. We’re delighted to support the team as they scale their platform and deliver meaningful impact for patients.”
The competitive landscape
IMU operates in one of the fastest-growing segments of biotechnology. Isomorphic Labs, the AI drug discovery company spun out of DeepMind, raised $2.1 billion in Series B funding in May. Owkin, the Paris-based AI biomedical research company, has raised $334 million in total and spun out a diagnostics subsidiary called Waiv with $33 million in fresh financing in March. Recursion Pharmaceuticals has raised hundreds of millions to build large-scale biological datasets for drug discovery using machine learning, and Nference applies AI to clinical and biomedical data to surface disease insights across healthcare systems.
What differentiates IMU is its exclusive focus on immune intelligence. Rather than targeting drug discovery in isolation, the company is building a foundational immune profiling standard that could underpin diagnosis, patient stratification, treatment monitoring, and therapeutic development across multiple disease areas simultaneously.
What’s next?
Healthcare is moving steadily toward precision medicine, where treatments are tailored to individual patients rather than broad populations. Achieving that vision requires a deeper understanding of biology than traditional diagnostic tools can provide. IMU believes the immune system may be the missing layer.
With one of the largest immune datasets ever assembled, proprietary AI analytics, and growing clinical validation, the company is positioning itself at the intersection of biotechnology, machine learning, and personalised medicine. IMU could help establish a new standard for immune profiling—one that changes not only how diseases are treated, but how they are understood in the first place.
